Welcome to the August edition of Changing Faces’ digital and supplier edition. This was a bit of a slower month, but it wasn’t completely without notable moves.
The fallout from the FDA's recent decision not to approve Lykos Therapeutics' psychedelic treatment has spread to its senior management, with chief executive Amy Emerson stepping down.
